Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2008

View Archived Issues

FDA assigns priority review status to sanofi-aventis' NDA for Multaq in atrial fibrillation

Study examines role of insulin signaling in early Alzheimer's disease

Studies in vitro, in vivo display activity of gamma-secretase inhibitor GSI-953

Novel vitamin/nutriceutical formulation improves cognitive decline and behavioral symptoms

Mechanism of action discovered for the novel TNF-alpha production inhibitor SA-13353

Recent highlights at Elan

Cortex reports positive results from RD-02 phase IIa clinical trial of Ampakine in RD

Sound's chemoprotectant drug cleared for phase II hearing loss trial

Hematide phase III program cleared to continue by DMC

Metabasis and Roche collaborate in HCV

New data on TMC-278, a next-generation NNRTI, presented at the International AIDS Conference

Xanodyne reports positive results from two phase III clinical trials of tranexamic acid

Geron initiates enrollment in phase I/II clinical trial of GRN-163L in breast cancer

GTC Biotherapeutics submits final portion of BLA for ATryn to FDA

Innocoll completes dosing in phase II clinical trial of CollaRx in postoperative pain

Archemix and Ribomic sign license agreement for aptamers against multiple targets

FDA extends review timeline by 3 months for Centocor's BLA for ustekinumab

Lixte's compounds for brain tumors demonstrate activity in pancreatic cancer models

Good antiviral activity of Achillion's elvucitabine in phase II study

Novel JAK3 inhibitors described in patent literature

Novel agents for diagnosis of AD discussed in Nihon Medi-Physics patent

New agents for gastrointestinal disorders revealed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...